Maxim Group Issues Pessimistic Forecast for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price

Theriva Biologics (NYSEAMERICAN:TOVX) had its price target cut by Maxim Group from $25.00 to $6.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Theriva Biologics Stock Performance

TOVX stock opened at $1.40 on Wednesday. Theriva Biologics has a 1 year low of $1.24 and a 1 year high of $17.11. The company has a market capitalization of $3.18 million, a P/E ratio of -0.04 and a beta of 1.34.

Theriva Biologics (NYSEAMERICAN:TOVX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($6.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.25) by ($0.56).

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.